Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725690 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL29753859 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL725689 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9022509 | 0.93 | ADORA2A (0.86) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9022511 | 0.93 | ADORA2A (0.86) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9021653 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL8838160 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL9021635 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL8838178 | 0.91 | ADORA2A (0.82) | CYP1A2ADORA2AADORA2BTHPOMEN1 | |
| SCHEMBL11846235 | 0.89 | CYP1A2 (0.80) | CYP1A2ADORA2AADORA2BTHPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255970-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2022036063-A2 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255970-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | YAP1, RELA, NFKBIA | CYP1A2 4465/4885ADORA2A 4761/4885ADORA2B 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.